Literature DB >> 15654469

[Tuberculosis in Salvador, Brazil: costs to health system and families].

João G Costa1, Andreia C Santos, Laura C Rodrigues, Mauricio L Barreto, Jennifer A Roberts.   

Abstract

OBJECTIVE: Tuberculosis is one the greatest causes of mortality worldwide, but its economic effects are not well known. This study had the objective of estimating the costs to the public and private healthcare systems and to families of tuberculosis treatment and prevention.
METHODS: This study was made in the municipality of Salvador, State of Bahia, Brazil, in 1999. Data for estimating the costs to the healthcare system were collected from the Department of Health, healthcare facilities and a philanthropic institution. The public and private costs were analyzed using cost accounting methodology. Cost data relating to families were collected by means of questionnaires, and included data on transportation, food and other expenses, and also income losses associated with this disease.
RESULTS: The average cost of treating one new case of tuberculosis was approximately US$103. The cost of treating one multiresistant patient was 27 higher than this. The cost to the public services consisted of 65% on hospitalization, 32% on treatment, and only 3% on prevention. The families committed around 33% of their income on expenses related to tuberculosis.
CONCLUSIONS: Despite the fact that the families did not have to pay for medications and treatment, given that this service is offered by the State, the costs to families related to loss of income due to the disease were very high. The proportion of public service funds utilized for prevention is small. Greater investment in prevention campaigns not only might diminish the numbers of cases but also might lead to earlier diagnosis, thus reducing the costs associated with hospitalization. The lack of an integrated cost accounting system makes it impossible to visualize costs across the various sectors.

Entities:  

Mesh:

Year:  2005        PMID: 15654469     DOI: 10.1590/s0034-89102005000100016

Source DB:  PubMed          Journal:  Rev Saude Publica        ISSN: 0034-8910            Impact factor:   2.106


  11 in total

Review 1.  A systematic review of health economic evaluations of vaccines in Brazil.

Authors:  Ana Marli Christovam Sartori; Luciana Martins Rozman; Tassia Cristina Decimoni; Roseli Leandro; Hillegonda Maria Dutilh Novaes; Patrícia Coelho de Soárez
Journal:  Hum Vaccin Immunother       Date:  2017-01-27       Impact factor: 3.452

Review 2.  Costs to Health Services and the Patient of Treating Tuberculosis: A Systematic Literature Review.

Authors:  Yoko V Laurence; Ulla K Griffiths; Anna Vassall
Journal:  Pharmacoeconomics       Date:  2015-09       Impact factor: 4.981

3.  Defining catastrophic costs and comparing their importance for adverse tuberculosis outcome with multi-drug resistance: a prospective cohort study, Peru.

Authors:  Tom Wingfield; Delia Boccia; Marco Tovar; Arquímedes Gavino; Karine Zevallos; Rosario Montoya; Knut Lönnroth; Carlton A Evans
Journal:  PLoS Med       Date:  2014-07-15       Impact factor: 11.069

Review 4.  Path of infectious diseases in Brazil in the last 50 years: an ongoing challenge.

Authors:  Eliseu Alves Waldman; Ana Paula Sayuri Sato
Journal:  Rev Saude Publica       Date:  2016-12-22       Impact factor: 2.106

5.  Costs of a successful public-private partnership for TB control in an urban setting in Nepal.

Authors:  Deepak K Karki; Tolib N Mirzoev; Andrew T Green; James N Newell; Sushil C Baral
Journal:  BMC Public Health       Date:  2007-05-18       Impact factor: 3.295

6.  Cost-effectiveness analysis of a state funded programme for control of severe asthma.

Authors:  Rosana Franco; Andreia C Santos; Harrison F do Nascimento; Carolina Souza-Machado; Eduardo Ponte; Adelmir Souza-Machado; Sebastião Loureiro; Maurício L Barreto; Laura C Rodrigues; Alvaro A Cruz
Journal:  BMC Public Health       Date:  2007-05-17       Impact factor: 3.295

7.  Smoking increases the risk of relapse after successful tuberculosis treatment.

Authors:  Joanna d'Arc Lyra Batista; Maria de Fátima Pessoa Militão de Albuquerque; Ricardo Arraes de Alencar Ximenes; Laura Cunha Rodrigues
Journal:  Int J Epidemiol       Date:  2008-06-13       Impact factor: 7.196

8.  Community-based DOTS and family member DOTS for TB control in Nepal: costs and cost-effectiveness.

Authors:  Tolib N Mirzoev; Sushil C Baral; Deepak K Karki; Andrew T Green; James N Newell
Journal:  Cost Eff Resour Alloc       Date:  2008-10-24

Review 9.  Financial burden for tuberculosis patients in low- and middle-income countries: a systematic review.

Authors:  Tadayuki Tanimura; Ernesto Jaramillo; Diana Weil; Mario Raviglione; Knut Lönnroth
Journal:  Eur Respir J       Date:  2014-02-13       Impact factor: 16.671

10.  Shortened first-line TB treatment in Brazil: potential cost savings for patients and health services.

Authors:  Anete Trajman; Mayara Lisboa Bastos; Marcia Belo; Janaína Calaça; Júlia Gaspar; Alexandre Martins Dos Santos; Camila Martins Dos Santos; Raquel Trindade Brito; William A Wells; Frank G Cobelens; Anna Vassall; Gabriela B Gomez
Journal:  BMC Health Serv Res       Date:  2016-01-22       Impact factor: 2.655

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.